Members → Templates → DA

Multi-national descriptive analysis builder

Characterise a population; how common a disease is, how a drug is used, who dies; across AsPEN sites. Standard output for Policy & Utilisation theme work and the denominator on which causal studies depend.

← All templates

Checking your session…

The protocol builder is currently restricted to AsPEN admins.

1 · Study identification

Study title Short ID Version · Date Lead investigator(s)

2 · Research question

Population What we measure Time window

3 · Sites

Tick every database (not just country). Feature chips show what each carries; for a descriptive protocol the denominator + the metric features need to match (e.g. cause-specific mortality needs Mortality linkage; DDD needs Rx; cancer-survivor cohorts need Cancer).

Legend Rx Prescriptions Dx Diagnoses Lab Lab results Img Imaging Mor Mortality linkage Can Cancer-registry linkage Preg Pregnancy / birth linkage Gen Genomics / biobank linkage

Taiwan

CGRD RxDxLabImgPreg NHIRD RxDxLabImgMorCanPreg TWB LabGen

South Korea

HIRA RxDxPreg NHIS-NHID RxDxLabMorCanPreg

Japan

DeSC Database RxDxLab JMDC Claims Database RxDxLabPreg Medical Data Vision (MDV) Database RxDxLab NDB RxDx

Hong Kong

CDARS RxDxLabImgMorCanPreg

Thailand

HDC RxDxLabMorPreg

Australia

PBS Rx VLHD RxDxMor

Finland

FinReg RxDxMorCanPreg

United Kingdom

CPRD RxDxMorCanPreg ISD RxDxLabMorCanPreg THIN RxDx UKB LabImgMorCanGen

Netherlands

PHARMO Database Network RxDxLabMorCan

United States

20% sample RxDxMorCan Medicaid RxDxMorPreg

Others (one per line)

⚠ Feasibility heads-up; not a blocker

Your chosen metrics or text imply data features that some selected sites don't carry. Cross-country descriptive studies often accommodate this by reporting which sites contribute to which metric; make that explicit in the per-site analytic plan.

4 · Population (denominator)

Validation citation auto-appends to References on export.

Population; name Operational definition Code set / criteria Inclusion criteria (one per line) Exclusion criteria (one per line) Index date / observation-start rule Study calendar period

5 · Numerator phenotypes

What you are counting in the numerator. Pick from each library as relevant; drug exposures for utilisation metrics, outcomes for incidence / prevalence, mortality causes for cause-specific mortality. Free-text fields below for codes not in the libraries.

Drug exposure; name Drug exposure; code set Outcome; name Outcome; code set Outcome; operational definition Cause of death; name Cause of death; code set

6 · Output metrics; what to report

Tick every metric to report. Each ticked metric gets its own section in the protocol output (Markdown + Word), with operational definition, formula, and unit. Mix-and-match freely; most descriptive AsPEN papers report 3-6 metrics.

Occurrence

Incidence rate New cases over person-time at risk. cases / 1000 person-years Period prevalence Cases ÷ cohort, over a calendar window. % of cohort in window Point prevalence Cases ÷ cohort on a single calendar date (annual / mid-year typical). % at index date

Mortality

All-cause mortality rate Requires mortality linkage at the site. deaths / 1000 person-years Cause-specific mortality Uses cause-of-death codes; see library. deaths / 1000 person-years

Utilisation

DDD / 1000 inhabitants / day WHO ATC/DDD index dose; classic drug-utilisation metric. DDD/1000/d Initiation rate Incident drug exposure rate. new users / 1000 person-years Persistence / discontinuation Time-to-discontinuation (Kaplan-Meier description). median days; % at 1 y Switching pattern (Sankey) First-line → second-line → … transitions. flows between drug classes Concomitant use Proportion using multiple drug classes within a window. % on ≥2 classes

Adjustment

Age-standardised rates Direct or indirect standardisation to a reference population. per 1000 (standardised)

Trends

Joinpoint / segmented trend Annual percent change with break-point detection (Kim 2000). APC / AAPC Trend-in-trend (Ji 2017) Advanced variant; exploits cross-region trend covariance. May spin off into its own template. RR via trend correlation

7 · Stratification

Report each ticked metric stratified by these variables (in addition to overall).

Age (5-year bands) Age (10-year bands) Age (≥65 vs <65) Sex (male vs female) Calendar year Country / site Index year stratum (5-year blocks) Urbanicity (urban / rural) Socioeconomic status / education Insurance plan / payer

Custom strata (one per line)

8 · Age-standardisation (active when "Age-standardised rates" is ticked above)

Reference population WHO 2000 is the most common for cross-country comparisons; ESP 2013 is preferred in European contexts. Method Age bands for standardisation

9 · Joinpoint / trend analysis (active when "Joinpoint trend" is ticked)

Trend year range Max joinpoints Segment-fit method Report

Trend-in-trend variant (Ji ECC et al, Pharmacoepidemiol Drug Saf 2017) is an advanced extension that exploits cross-region covariance between exposure-trend and outcome-trend; useful when a policy interruption affects exposure unevenly across AsPEN sites. If you ticked "Trend-in-trend" in Section 6 above, the protocol will include a methods stub describing this design; consider spinning it off into its own protocol if the trend-in-trend logic is the central analytic question.

10 · Statistical analysis

Rate / proportion confidence intervals Cross-site comparison Site contribution Suppression / small-cell rule

11 · Sensitivity analyses

Alternative denominator definition (mid-year vs annual average vs Lexis triangle) Alternative time-window length (calendar-year vs fiscal-year vs rolling 12-month) Restrict to incident users only (vs all users) Restrict to ≥1 year of baseline observation Negative-control outcome; should show null / flat trend Exclude index-year transition (washout 30 / 60 / 90 d) Alternative case-finding rule (≥1 inpatient vs ≥2 outpatient vs algorithm) Sub-divide by data-source quality (full vs partial linkage) Limit to sites with ≥X years of follow-up to reduce small-sample noise

Custom sensitivity analyses (one per line)

12 · Execution & timeline

Architecture

Timeline preset

Milestones (one per line)

13 · Ethics, dissemination, references (optional)

Ethics Dissemination Key references (one per line)

Lai EC, Stang P, Yang YHK, Kimura S, Wong IC, Setoguchi S. International multi-database pharmacoepidemiology: potentials and pitfalls. Curr Epidemiol Rep 2015 (AsPEN database survey foundation; PMID 26133022).
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19(3):335-51.
Ji X, Small DS, Leonard CE, Hennessy S. The Trend-in-Trend research design for causal inference. Epidemiology 2017;28(4):529-36.
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time-series studies in medication use research. J Clin Pharm Ther 2002;27(4):299-309.
WHO. Age-standardisation of rates: a new WHO standard. GPE Discussion Paper 31, 2001 (Ahmad OB et al).
Tan EC, Pratt NL, Ilomäki J et al. Multi-country comparison of polypharmacy. Pharmacoepidemiol Drug Saf 2023 (PMID 36821644).
Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai EC. Taiwan's NHIRD: past and future. Clin Epidemiol 2019;11:349-58.
Shao SC, Chan YY, Kao Yang YH, Lin SJ, Hung MJ, Chien RN, Lai CC, Lai EC. The Chang Gung Research Database. Pharmacoepidemiol Drug Saf 2019;28(5):593-600.

Live preview

Auto-saved to this browser

Validated phenotype library

Pick a phenotype

Submit to AsPEN office

Send protocol draft

Working title

Lead; name Lead; email

Description (summary from your draft)

Sites will be carried over from your draft.

Why this study? *